At a glance
- Originator Fujisawa
- Class Neuroprotectants; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Adenosine A1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypotension; Renal failure
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 31 Jan 2005 This compound is still in active development for hypotension
- 16 Jun 2004 Data presented at the 41st Congress of the European Renal Association and the European Dialysis and Transplant Association (ERA-EDTA-2004) have been added to the Vascular Disorders therapeutic trials section